U.S. Markets closed

Earnings Review and Free Research Report: Advanced Accelerator’s Revenue Increased 32%

Research Desk Line-up: Neogen Post Earnings Coverage

LONDON, UK / ACCESSWIRE / September 22, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Advanced Accelerator Applications S.A. (NASDAQ: AAAP) ("Advanced Accelerator"), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=AAAP, following the Company's reporting of its financial results on August 31, 2017, for the second quarter of the fiscal year 2017. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member's account at:


Get more of our free earnings reports coverage from other constituents of the Diagnostic Substances industry. Pro-TD has currently selected Neogen Corporation (NASDAQ: NEOG) for due-diligence and potential coverage as the Company announced on September 19, 2017, its financial results for Q1 FY18 which ended on August 31, 2017. Register for a free membership today, and be among the early birds that get access to our report on Neogen when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on AAAP; also brushing on NEOG. With the links below you can directly download the report of your stock of interest free of charge at:



Earnings Reviewed

For the three months ended June 30, 2017, Advanced Accelerator's revenue increased 32% to €36.53 million from €27.64 million in Q2 FY16. The increase was primarily driven by the PET product category, which increased 50% to €25.2 million on a y-o-y basis.

During Q2 FY17, Advanced Accelerator's adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) was negative €2.17 million compared to positive €2.27 million in Q2 FY16. For the reported quarter, the Company's adjusted EBITDA margin was negative 5.93% of revenue compared to positive 8.2% of revenue in Q2 FY16.

For the reported quarter, Advanced Accelerator's D&A expenses increased 18% to €3.81 million from €3.23 million in Q2 FY16.

During Q2 FY17, Advanced Accelerator's operating loss was €5.98 million compared to an operating loss of €963,000 in Q2 FY16. The increase in operating loss was due to higher personnel costs and operating expenses, primarily related to the launch of new products, ongoing pipeline development, and increases in stock option grants to employees and compliance requirements.

During Q2 FY17, Advanced Accelerator's net loss was €9.91 million compared to a net loss of €1.43 million in Q2 FY16. During Q2 FY17, Advanced Accelerator's diluted earnings per share (EPS) was negative €0.11 compared to negative €0.02 in Q2 FY16.

On August 30, 2017, Advanced Accelerator's announced that the US Food and Drug Administration (FDA) has accepted and considered complete the resubmission of the New Drug Application (NDA) for its investigational drug lutetium Lu 177 dotatate (Lutathera).

Balance Sheet

As on June 30, 2017, Advanced Accelerator's cash and cash equivalents decreased 21.2% to €174.95 million from €222.08 million in Q4 FY16.

During Q2 FY17, the Company's trade and other receivables increased 17.1% to €36.38 million from €31.08 million in Q4 FY16.

For the reported quarter, Advanced Accelerator's inventories increased 18.3% to €9.58 million from €8.10 million in Q4 FY16.

During Q2 FY17, the Company's trade and other payables increased 20 basis points to €20.16 million from €20.12 million in Q4 FY16.

For the reported quarter, the Company's Return on Equity (ROE) ratio was negative 3.46% compared to negative 0.85% in Q2 FY16.

During Q2 FY17, the Company's Return on Assets (ROA) ratio was negative 9.94% compared to negative 2.07% in Q2 FY16.

During H1 FY17, Advanced Accelerator's cash provided by operating activities was negative €8.74 million compared to negative €6.43 million in H1 FY16.

Stock Performance

At the closing bell, on Thursday, September 21, 2017, Advanced Accelerator Applications' stock marginally fell 0.85%, ending the trading session at $57.15. A total volume of 155.99 thousand shares have exchanged hands, which was higher than the 3-month average volume of 107.57 thousand shares. The Company's stock price soared 44.17% in the last three months, 44.39% in the past six months, and 48.75% in the previous twelve months. Moreover, the stock skyrocketed 113.57% since the start of the year. The stock currently has a market cap of $2.53 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily